{"id":469705,"date":"2021-04-01T09:03:17","date_gmt":"2021-04-01T13:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=469705"},"modified":"2021-04-01T09:03:17","modified_gmt":"2021-04-01T13:03:17","slug":"medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/","title":{"rendered":"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic"},"content":{"rendered":"
\n

BURBANK, Calif., April 01, 2021 (GLOBE NEWSWIRE) — via NewMediaWire<\/u><\/a> — Medolife Rx, Inc. (“Medolife”),\u00a0a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that Dr. Ram\u00f3n Feliz MD, PhD, an oncological surgeon practicing medicine in the Dominican Republic, has made an official recommendation for inclusion of Medolife\u2019s drug candidate Escozine\u00ae in treatment regimens for patients with various forms of cancer including pancreatic, breast, prostate, and different segments of colon cancer.<\/p>\n

Medolife has completed extensive pre-clinical and clinical research on Escozine\u00ae as a potential therapeutic for various types of cancer. After observing the research and reviewing the data, the esteemed doctor made a formal recommendation to begin use of Escozine\u00ae in cancer therapies. He came to the conclusion, as noted in his formal recommendation, after making clinical observations that patients who used Escozine\u00ae as a part of their cancer therapeutics regimen saw:<\/p>\n

–\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Improvements in their quality of life<\/p>\n

–\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Decreased intensity of pain in affected areas<\/p>\n

–\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Decreases in the diameter of tumor masses<\/p>\n

–\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Improvement in their sleep conditions<\/p>\n

–\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Prolonged life span<\/p>\n

–\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 No observed side effects<\/p>\n

The doctor also endorsed further clinical investigations on Escozine\u00ae as a cancer therapeutic, which Medolife is currently conducting in both the United States and the Dominican Republic. It recently announced pre-clinical results on Escozine\u2019s efficacy in eliminating cell lines in ovarian and bladder cancer whereas it eradicated the cell lines completely, creating a path forward for Escozine\u00ae as a cancer-fighting drug, along with its life-improvement benefits.<\/p>\n

\u201cAfter having witnessed the positive effects that Escozine\u00ae had on patients with cancer in pre-clinical studies, Dr. Feliz was so impressed he took it upon himself to recommend its use almost immediately,\u201d said Medolife CEO Dr. Arthur Mikaelian. \u201cWhile we must continue our official clinical research in order to obtain regulatory approval for Escozine\u00ae as a cancer therapeutic, it is becoming more clear that it is not only effective in improving the lives of cancer patients but also in fighting cancer itself. This is beyond encouraging. We are so appreciative of Dr. Feliz\u2019s support and plan to continue to work with him and other researchers to further prove Escozine\u2019s efficacy and bring products to market as quickly as possible. Many patients desperately need access and we will fulfill our mission of bringing life-saving therapeutics to patients who need them most.\u201d<\/p>\n

Escozine\u00ae is Medolife\u2019s lead drug candidate that is undergoing clinical trials for both cancer and SARS-CoV-2 (COVID-19) therapeutics. It is derived from a small molecular peptide found in scorpions that is then polarized through a patented process developed by Medolife\u2019s founder Dr. Mikaelian. The polarization process increases the efficacy and bioavailability of the active pharmaceutical ingredients in any polarized drug, requiring less dosage and leading to a decrease in side effects.\u00a0Currently, Medolife is awaiting product registration for Escozine\u00ae in the Dominican Republic as a treatment for COVID-19. It has also filed data on Escozine\u00ae with the United States Food and Drug Administration (FDA) where it is seeking an Investigational New Drug (IND) approval pathway.<\/p>\n

\n About Medolife Rx<\/strong>\n <\/p>\n

Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company\u2019s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company\u2019s lead clinical development programs include Escozine\u00ae, a proprietary formulation consisting of small molecule peptides derived from\u00a0Rhopalurus princeps<\/em>\u00a0scorpions, which is amplified by the Company\u2019s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine\u00ae and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.\u00a0<\/p>\n

Through its subsidiary\u00a0QuantRx<\/a>, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian\u2019s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta’s mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.<\/p>\n

Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company’s expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “we believe,” “we intend,” “may,” “will,” “should,” “could,” and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company’s filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.<\/p>\n

Contacts:
Phil Sands
https:\/\/ir.quantrx.com\/<\/u><\/a>
818-659-8052<\/p>\n

Kyle Porter
medolife@cmwmedia.com
858-264-6600<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BURBANK, Calif., April 01, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medolife Rx, Inc. (“Medolife”),\u00a0a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that Dr. Ram\u00f3n Feliz MD, PhD, an oncological surgeon practicing medicine in the Dominican Republic, has made an official recommendation for inclusion of Medolife\u2019s drug candidate Escozine\u00ae in treatment regimens for patients with various forms of cancer including pancreatic, breast, prostate, and different segments of colon cancer. Medolife has completed extensive pre-clinical and clinical research on Escozine\u00ae as a potential therapeutic for various types of cancer. After observing the research and reviewing the data, the esteemed doctor made a formal … <\/p>\n

Continue reading “Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-469705","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMedolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BURBANK, Calif., April 01, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medolife Rx, Inc. (“Medolife”),\u00a0a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that Dr. Ram\u00f3n Feliz MD, PhD, an oncological surgeon practicing medicine in the Dominican Republic, has made an official recommendation for inclusion of Medolife\u2019s drug candidate Escozine\u00ae in treatment regimens for patients with various forms of cancer including pancreatic, breast, prostate, and different segments of colon cancer. Medolife has completed extensive pre-clinical and clinical research on Escozine\u00ae as a potential therapeutic for various types of cancer. After observing the research and reviewing the data, the esteemed doctor made a formal … Continue reading "Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T13:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic\",\"datePublished\":\"2021-04-01T13:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/\"},\"wordCount\":1067,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/\",\"name\":\"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ==\",\"datePublished\":\"2021-04-01T13:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/","og_locale":"en_US","og_type":"article","og_title":"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic - Market Newsdesk","og_description":"BURBANK, Calif., April 01, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medolife Rx, Inc. (“Medolife”),\u00a0a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that Dr. Ram\u00f3n Feliz MD, PhD, an oncological surgeon practicing medicine in the Dominican Republic, has made an official recommendation for inclusion of Medolife\u2019s drug candidate Escozine\u00ae in treatment regimens for patients with various forms of cancer including pancreatic, breast, prostate, and different segments of colon cancer. Medolife has completed extensive pre-clinical and clinical research on Escozine\u00ae as a potential therapeutic for various types of cancer. After observing the research and reviewing the data, the esteemed doctor made a formal … Continue reading \"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T13:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic","datePublished":"2021-04-01T13:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/"},"wordCount":1067,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/","name":"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ==","datePublished":"2021-04-01T13:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk1MCM0MTAxNjk4IzUwMDA3ODI1NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medolife-rxs-lead-drug-candidate-escozine-recommended-by-doctor-for-use-in-cancer-treatment-regimen-in-dominican-republic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medolife Rx\u2019s Lead Drug Candidate Escozine\u00ae Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=469705"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469705\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=469705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=469705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=469705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}